Results 221 to 230 of about 115,119 (287)

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg, Jesus M. Banales, Gideon Hirschfield, Palak Trivedi, Edward E. Cable, Charles A. McWherter, Andrew N. Billin, Daria B. Crittenden, Grant Budas   +8 more
wiley   +1 more source

Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain

British Journal of Pharmacology, Volume 183, Issue 9, Page 2009-2027, May 2026.
Abstract Background and Purpose Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might ...
Maria Fernanda Pessano Fialho, Raquel Tonello, Evelyne Silva Brum, Gabriela Becker, Nigel W. Bunnett, Sara Marchesan Oliveira   +5 more
wiley   +1 more source

TNF‐α partially modulates the endothelial dysfunction during the acute phase of Trypanosoma cruzi infection

British Journal of Pharmacology, Volume 183, Issue 10, Page 2256-2272, May 2026.
Background and Purpose Whereas the effects of Trypanosoma cruzi (T. cruzi) infection are well‐characterised in the heart, its impact on the vasculature has received little attention. In this study, we investigated the effects of acute and chronic T. cruzi infection on vascular responsiveness and the underlying mechanisms.
Thales M. H. Dourado, Wanessa M. C. Awata, Gustavo F. Pimenta, Barbara M. Marchetti, Maiara V. Providello, Sérgio De Albuquerque, Carlos R. Tirapelli   +6 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Clinical manifestations, prognostic impact, and relapse in polyarteritis nodosa: a systematic review and meta-analysis. [PDF]

Rheumatol Int
Taprantzis N, Kasimeri ME, Chrysikos D, Shihada A, Samolis A, Tsakotos G, Liga M, Troupis T.   +7 more
europepmc   +1 more source

First‐In‐Human Safety, Pharmacokinetics, and Pharmacodynamics of VENT‐02 Freebase, a CNS‐Penetrant NLRP3 Inhibitor

Clinical and Translational Science, Volume 19, Issue 5, May 2026.
ABSTRACT The NLRP3 inflammasome is a central mediator of innate immunity and a key driver of inflammatory and neurodegenerative diseases. VENT‐02 is orally bioavailable, central nervous system‐penetrant, selective small‐molecule inhibitor of NLRP3. This first‐in‐human, randomized, double‐blind, placebo‐controlled study assessed the safety, tolerability,
Lisanne C. A. Smidt, Matthijs Moerland, Manon A. A. Jansen, Philip H. C. Kremer, Alexandra A. J. Sille, Pamela K. Strugala, Erica S. Klaassen, Anick Auger, Silvana Jananji, Rania Faidi, Kelly A. Pike, Loraine Warner, Andre Matta, Xavier Valencia, Ofer Spiegelstein   +14 more
wiley   +1 more source

Clarifying the Diagnosis of Epstein-Barr Virus Related Myositis in a Genetically Confirmed Mitochondrial Diabetes Patient. [PDF]

Eur J Case Rep Intern Med
Picolos MK, Kyriakidou A, Papapostolou A, Papaetis GS.   +3 more
europepmc   +1 more source

Clinical and Epidemiological Characteristics of an Oropouche Virus Outbreak in Loreto, Peru (October 2024-March 2025). [PDF]

Pathogens
Rojo-Pérez MÁ, Ramírez-García EA, Llenas-García J.   +2 more
europepmc   +1 more source

Late-Onset Ocular Myasthenia Gravis-Like Symptoms During Erenumab Therapy for Chronic Migraine: A Case Report. [PDF]

Biologics
Qaqish A, Al Anber A, Abdelhafez G.
europepmc   +1 more source

RDC/TMD axis II criteria in defining temporomandibular disorders. a cross-sectional study. [PDF]

BMC Oral Health
Ardıç M, Ardıç MY, Kahraman B, Bozkurt P, Üçok C.   +4 more
europepmc   +1 more source